Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GlyT-1 Inhibitor Treatment for Refractory Schizophrenia and Its Effects on NMDA Modulation

NCT01251055 is registered in ClinicalTrials.gov with China Medical University Hospital as lead sponsor.

NCT NCT01251055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01251055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GlyT-1 Inhibitor Treatment for Refractory Schizophrenia and Its Effects on NMDA Modulation
Lead sponsor
China Medical University Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2010
Completion date
October 31, 2013
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia, treatment refractory